Skip to main content

CORRECTION article

Front. Pharmacol., 25 August 2022
Sec. Experimental Pharmacology and Drug Discovery
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1002649

Corrigendum: Nanostructured lipid carrier–mediated transdermal delivery of aceclofenac hydrogel present an effective therapeutic approach for inflammatory diseases

This article is a correction to:

  1. Synergistic Anti-MRSA Activity of Cationic Nanostructured Lipid Carriers in Combination With Oxacillin for Cutaneous Application

    1. Read original article
Neeraj K. Garg&#x;Neeraj K. Garg1†Nikunj Tandel&#x;Nikunj Tandel2†Sanjay Kumar BhadadaSanjay Kumar Bhadada3Rajeev K. Tyagi Rajeev K. Tyagi4*
  • 1University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
  • 2Institute of Science, Nirma University, Ahmedabad, India
  • 3Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
  • 4Division of Cell Biology and Immunology, Biomedical Parasitology and Nano-Immunology Lab, CSIR-Institute of Microbial Technology (IMTECH), Chandigarh, India

A Corrigendum on
Nanostructured lipid carrier–mediated transdermal delivery of aceclofenac hydrogel present an effective therapeutic approach for inflammatory diseases

by Garg NK, Tandel N, Bhadada SK and Tyagi RK (2021). Front. Pharmacol. 12:713616. doi: 10.3389/fphar.2021.713616

In the original article, there was an error in Figure 2 as published. By mistake, an incorrect image for Figure 2A was supplied. The corrected Figure 2 appears below.

FIGURE 2
www.frontiersin.org

FIGURE 2. Microscopic analysis of shape and size of prepared formulations. (A) HR-TEM analysis and (B) SEM analysis of ACE-loaded CA-NLCs.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: aceclofenac, nanostructured lipid carrier, rheological behavior, texture profile, transdermal delivery

Citation: Garg NK, Tandel N, Bhadada SK and Tyagi RK (2022) Corrigendum: Nanostructured lipid carrier–mediated transdermal delivery of aceclofenac hydrogel present an effective therapeutic approach for inflammatory diseases. Front. Pharmacol. 13:1002649. doi: 10.3389/fphar.2022.1002649

Received: 25 July 2022; Accepted: 29 July 2022;
Published: 25 August 2022.

Edited and reviewed by:

Letizia Polito, University of Bologna, Italy

Copyright © 2022 Garg, Tandel, Bhadada and Tyagi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Rajeev K. Tyagi, rajeevtyagi@imtech.res.in, rajeev.gru@gmail.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.